Buy or sell PIQUR Therapeutics stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
PIQUR Therapeutics Stock
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
About PIQUR Therapeutics Stock
PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the University of Basel, focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. Both PI3K and mTOR are clinically validated drug targets in oncology. PIQUR has a secured patent scope protecting many chemical compounds.
Funding History
| August 2013 | $5.0M |
|---|---|
| March 2014 | $32.0M |
| July 2015 | $19.0M |
| September 2017 | $29.8M |
Management
Chief Scientific Officer
Doriano Fabbro
Head BD & Communications
Tatsuo Satoh
Head Drug Discovery
Paul Hebeisen
Head of Preclinical Safety & Toxicology
Robert Ettlin
COO/CMO
Melanie Rolli
CFO
Martin Gasser
Head QA
Christine Wurz
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
